TNFRSF17 and AL amyloidosis: Subsequently, the first-in-human Phase I clinical trial to evaluate the efficacy of BCMA-targeted CAR T-cells in relapsed/refractory multiple myeloma (RRMM) was conducted (NCT02215967) [33, 34].